Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non–Small Cell Lung Cancer

Published:2019-10-01 Issue:10 Volume:5 Page:1464
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Rengan Ramesh¹²,Mick Rosemarie³,Pryma Daniel A.⁴,Lin Lilie Leming⁵,Christodouleas John¹⁶,Plastaras John P.¹,Simone Charles B.⁷,Gupta Anjali K.¹,Evans Tracey L.⁸,Stevenson James P.⁹,Langer Corey J.⁷,Kucharczuk John¹⁰,Friedberg Joseph¹¹,Lam Sarah¹,Patsch Dana¹,Hahn Stephen M.⁵,Maity Amit¹

Affiliation:

1. Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia

2. currently, Department of Radiation Oncology, University of Washington School of Medicine, Seattle

3. Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania School of Medicine, Philadelphia

4. Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia

5. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas

6. Medical Affairs and Clinical Research, Elekta, Atlanta, Georgia

7. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore

8. Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia

9. Division of Hematology-Oncology, Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio

10. Division of Thoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia

11. Division of Thoracic Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2748893/jamaoncology_rengan_2019_oi_190051.pdf

Reference26 articles.

1. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.;Bradley;Lancet Oncol,2015

2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer.;Aupérin;J Clin Oncol,2010

3. Non-small cell lung cancer clinical practice guidelines in oncology.;Ettinger;J Natl Compr Canc Netw,2006

4. Targeting tumor cells by enhancing radiation sensitivity.;McKenna;Genes Chromosomes Cancer,2003

5. Clinical target promiscuity: lessons from ras molecular trials.;Rengan;Cancer Metastasis Rev,2008

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conformational diversity and protein–protein interfaces in drug repurposing in Ras signaling pathway;Scientific Reports;2024-01-12

2. A Systematic Review of Literatures: To Identify Non-Cancer Drugs Repurposed for Lung Cancer;2023-12-04

3. Targeting PRSS23 with tipranavir induces gastric cancer stem cell apoptosis and inhibits growth of gastric cancer via the MKK3/p38 MAPK-IL24 pathway;Acta Pharmacologica Sinica;2023-10-09

4. New targets for old drugs;New Horizons in Natural Compound Research;2023

5. Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins;Nature Communications;2022-10-24